EU's CHMP Delays Decision On Actos, Restricts Use Of An NSAID And Cytoprotective
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe's top regulatory advisory panel wants further analysis of Actos' link with bladder cancer, but recommends limiting indications for the NSAID nimesulide and adding contraindications for the cytoprotective dexrazoxane.